Index

Acute intermittent porphyria (AIP), diagnosis and treatment of case study on, 162
diagnosis, 162, 164
EMG/nerve conduction studies, 163, 165
treatment, 164
Acute polyneuropathies, 162
Akinetic mutism, 77
Alcohol abuse. See Low-voltage fast beta pattern
Alpha coma
ancillary testing, 20
clinical correlation, 20
clinical evaluation, 20
differential diagnosis, 20
EEG recording, 21
etiology, 20
prognosis, 20
treatment, 20
Alpha frequency patterns (AFPs), 20–21
ALS. See Amyotrophic lateral sclerosis (ALS)
Altered mental status, definition of, 1
Amyotrophic lateral sclerosis (ALS), 122, 174
ancillary testing, 122
clinical correlates, 122
clinical evaluation, 122
differential diagnosis, 122
nerve conduction studies, 123
prognosis, 122
treatment, 122–3
Anesthetic agent, in SE, 61–2, 64, 66
Anoxic coma, prognostic value of SSEP in ancillary testing, 92
clinical correlates, 92
clinical evaluation, 92
differential diagnosis, 92
etiology, 92
prognosis, 92–3
Antiepileptic drugs, 14
Anti-epileptic drugs (AEDs), 30, 40
BIPLEDs and, 44
and frontal lobe seizures, 52
and occipital lobe seizures, 58
parietal lobe partial seizures and, 56
in PLEDS, 40
in simple partial status epilepticus, 66, 68
temporal lobe seizures and, 54
Babinski reflexes, in hypoglycemia, 32
Baclofen, 26
Baclofen toxicity
ancillary testing, 28
clinical correlation, 28
clinical evaluation, 28
differential diagnosis, 28
EEG pattern, 29
etiology, 28
prognosis, 28
prognosis, 28
treatment, 28
Benzodiazepine, 4, 28, 40, 44, 61–2, 66, 68, 82, 155
Beta, diffuse and frontal fast activity
ancillary testing, 4
clinical correlates, 4
clinical evaluation, 4
differential diagnosis, 4
EEG pattern, 5
etiology, 4
medication effect and, 5
prognosis, 4
Beta frequency bands, 5
Bicuculline-insensitive GABA-B receptors, 28
Bilateral independent PLEDs (BIPLEDs)
ancillary testing, 44
clinical correlates, 44
definition, 44
differential diagnosis, 44
EEG recording, 45
etiology, 44
frequency of discharges, 44
prognosis, 44
treatment, 44
Botulism, diagnosis and treatment of case study on, 166–8
Brachial plexopathy
ancillary testing, 128
clinical correlates, 128
Brachial plexopathy (cont.)
clinical evaluation, 128
differential diagnosis, 128
needle EMG examination, 129
nerve conduction studies, 128
prognosis, 128
treatment, 128
Brainstem auditory evoked potentials (BAEPs), 94, 97
in worsening hearing, 110–11
Burst/suppression
ancillary testing, 26
clinical correlate, 26
clinical evaluation, 26
differential diagnosis, 26
EEG pattern, 27
etiology, 26
prognosis, 26
treatment, 26
Catatonia, 73, 82, 84, 88, 91, 154
ancillary testing, 90
clinical correlates, 90
clinical evaluation, 90
differential diagnosis, 90
EEG recording, 91
etiology, 90
Coma, 76, 82, 84, 88, 90, 152, 154
EEG of, 77–8
Glasgow coma scale, 75
Comatose patients, 62, 64, 68, 70–71, 75, 97, 110
Complex partial status epilepticus (CPSE), 64
of frontal region. See Complex partial status epilepticus, frontal
of temporal region. See Complex partial status epilepticus, temporal
Complex partial status epilepticus, frontal
ancillary testing, 62
clinical correlates, 62
clinical evaluation, 62
differential diagnosis, 62
EEG pattern, 63
etiology, 62
prognosis, 62
treatment, 62
Complex partial status epilepticus, temporal
ancillary testing, 64
clinical correlates, 64
clinical evaluation, 64
differential diagnosis, 64
EEG pattern, 65
etiology, 64
prognosis, 64
treatment, 64
Compound muscle action potential (CMAP), 166
Confusion, definition of, 1
Consciousness
arousal, 76
awareness, 76
definition of, 76
Convulsive status epilepticus (CSE), 61
Critical illness neuromyopathy
ancillary testing, 124
clinical correlates, 124
clinical evaluation, 124
differential diagnosis, 124
needle EMG, 125
nerve conduction studies, 126
prognosis, 124
treatment, 124
Delirium, definition of, 1
Delta, diffuse and slow activity
ancillary testing, 8
clinical correlation, 8
clinical evaluation, 8
differential diagnosis, 8
EEG pattern, 9–10
etiology, 8
prognosis, 8
Diabetic amyotrophy, diagnosis and treatment of
EEG, 2, 88, 90
alpha coma, 21
anoxic coma, 79
baclofen toxicity, 29
BIPLEDs, 44–5
bursts of epileptiform activity with suppression periods, 27
coma, 77–8
diffuse alpha activity in coma, 21
frontal intermittent delta activity, 13
frontal lobe seizures, 52–3
generalized suppression with no cortical activity, 25
hypoglycemia, 33
in LIS, 78, 83
lithium toxicity, 31
low-voltage fast beta pattern, 19
medium- to high-voltage diffuse fast beta pattern, 5
occipital blindness and seizures, 150
occipital intermittent rhythmic delta activity, 15
occipital lobe seizures, 59
parietal lobe seizures, 57
PLEDs, 40–41
slow delta activity, 10
spindle coma, 23
temporal lobe seizures, 55
theta activity, 5
triphasic waves, 17
for V5, 78, 84–5
widespread arrhythmic delta pattern, 9
Electrocerebral inactivity, 25
Electromyography (EMG), 114, 124, 130
EMG. See Electromyography (EMG)
Encephalopathy, definition of, 1
Epilepsia partialis continua, 52, 62
Epilepsy monitoring, 49
EPs. See Evoked potentials (EPs)
Evoked potentials (EPs), 97
brainstem auditory evoked potentials, 97
role in coma prognosis, 78
somatosensory evoked potentials, 97
visual evoked potentials, 97
in VS patients, 78, 84
Eye blink artifact, 7
Eye deviation, 68–9
Eye leads, 12–13
Eye movement artifact, and FIRDA, 12–13
Femoral neuropathy
ancillary testing, 130
clinical correlates, 130
clinical evaluation, 130
differential diagnosis, 130
etiology, 130
needle EMG examination, 131
nerve conduction studies, 130–31
treatment, 130
Focal arrhythmic (polymorphic) delta activity
ancillary testing, 36
clinical correlates, 36
clinical evaluation, 36
definition, 36
differential diagnosis, 36
EEG pattern, 37
etiology, 36
Frontal glioma with complex partial seizures, case study on,
156–7
Frontal intermittent rhythmic delta activity
(FIRDA)
ancillary testing, 12
clinical correlates of, 12
clinical evaluation, 12
differential diagnosis, 12
EEG pattern, 13
in elderly patients, 12
etiology, 12
and eye movement artifact, 12–13
prognosis, 12
Frontal lobe partial seizures
ancillary testing, 52
clinical correlates, 52
clinical evaluation, 52
differential diagnosis, 52
EEG recording, 53
etiology, 52
prognosis, 52
treatment, 52
Functional magnetic resonance imaging (fMRI), 76–7,
82
comma, 78
MCS, 77
responses to language stimuli, study of, 79
Gait and posture testing, 114
Generalized nonconvulsive status epilepticus (GNSE), 64, 70,
158
clinical correlates, 70
clinical evaluation, 70
differential diagnosis, 70
EEG recording, 71–2
etiology, 70
prognosis, 70
treatment, 70
Generalized periodic epileptiform discharges (GPEDs), 46–7
ancillary testing, 46
clinical correlates, 46
clinical evaluation, 46
differential diagnosis, 46
EEG recording, 47
etiology, 46
prognosis, 46
treatment, 46
Glasgow coma scale, 20, 22, 26, 70, 75, 82, 84, 92, 94, 152
GNSE. See Generalized nonconvulsive status epilepticus (GNSE)
Guillain-Barré syndrome (GBS)
ancillary testing, 136
clinical correlates, 136
clinical evaluation, 136
differential diagnosis, 136
EMG/nerve conduction study, 137–8
prognosis, 136
treatment, 136
Head trauma, prognostic value of SSEP in
ancillary testing, 94
clinical considerations, 94
clinical correlates, 94
clinical evaluation, 94
differential diagnosis, 94
prognosis, 94–5
HIV-related DSPN, diagnosis and treatment of
case study on, 170
Hollow skull phenomenon, 78
Hypoglycemia
ancillary testing, 32
clinical correlates, 32
clinical evaluation, 32
differential diagnosis, 32
EEG pattern, 33
etiology, 32
prognosis, 32
treatment, 32
Index

Limbic encephalopathy
ancillary testing, 34
clinical correlates, 34
clinical evaluation, 34
differential diagnosis, 34
EEG pattern, 35
etiology, 34
Limbic status epilepticus from mycoplasma pneumonia, case study on, 154–5
LIS. See Locked-in syndrome (LIS)
Lithium toxicity
ancillary testing, 30
clinical correlates, 30
clinical evaluation, 30
differential diagnosis, 30
EEG pattern in, 31
etiology, 30
prognosis, 30
treatment, 30
Locked-in syndrome (LIS), 73, 75, 84, 88, 90, 152, 154
ancillary testing, 82
clinical correlates, 82
clinical evaluation, 82
definition of, 77
differential diagnosis, 82
EEG of, 78
EEG recording, 83
PET findings in, 78
prognosis, 83
treatment, 83
Long-latency auditory responses (N70), 78
Lorazepam, 16, 28, 30, 46, 61, 64, 68, 70
Low-voltage fast beta pattern
ancillary testing, 18
clinical correlates, 18
clinical evaluation, 18
differential diagnosis, 18
EEG recording, 19
etiology, 18
prognosis, 18
Low-voltage suppressed pattern
ancillary testing, 24
clinical correlation, 24
clinical evaluation, 24
differential diagnosis, 24
EEG report with no cortical activity, 25
etiology, 24
prognosis, 24
Lumbar radiculopathy
ancillary testing, 134
clinical correlates, 134
clinical evaluation, 134
differential diagnosis, 134
EMG/nerve conduction study, 134–5
prognosis, 134
treatment, 134
Minimally conscious state (MCS), 73, 75–7
ancillary testing, 88
clinical correlates, 88
clinical evaluation, 88
definition of, 76
differential diagnosis, 88
EEG recordings, 89
etiology, 88
and fMRI findings, 76–7
prognosis, 88
treatment, 88–9
Multifocal motor neuropathy (MMN), diagnosis and treatment of
 case study on, 174–6
Muscle artifact, 9, 57, 67
Muscle testing, 113
Myasthenia gravis (MG)
anncillary testing, 140
clinical correlates, 140
clinical evaluation, 140
differential diagnosis, 140
EMG/nerve conduction study, 140–41, 143–4
etiology, 140
treatment, 140
Myositis
ancillary testing, 142
clinical correlates, 142
clinical evaluation, 142
differential diagnosis, 142
prognosis, 142
treatment, 143
NCSE. See Nonconvulsive status epilepticus (NCSE)
Neuromuscular disorders, 113
clinical evaluation of, 116
diagnosing of, 113–14
in ICU patients, causes of, 115
laboratory evaluation of, 117
segmental weakness and sensory loss in, 119–20
weakness in, 113
Neuromuscular junction dysfunction, 166. See also Botulism, diagnosis and treatment of
Neuropathic syndromes during HIV infection, 170
Nonconvulsive status epilepticus (NCSE), 1, 16, 28, 30, 61, 70, 90, 158. See also Complex partial status epilepticus (CPSE)

Occipital blindness and seizures, case study on, 150–51
Occipital epileptic activity, 68
Occipital intermittent rhythmic delta activity (OIRDA)
anncillary testing, 14
in children, 14
clinical correlates, 14
clinical evaluation, 14
EEG pattern, 15
etiology, 14
Index 185

Index 185

prognosis, 14

treatment, 14

Occipital lobe simple partial seizures
ancillary testing, 58
clinical correlates, 58
clinical evaluation, 58
differential diagnosis, 58
EEG recording in, 59
etiology, 58
prognosis, 58
treatment, 58

Organ dysfunction
and diffuse slow theta activity, 6–7

Paralysis and respiratory failure in the ICU, causes of, 115

Parietal lobe simple partial seizures
ancillary testing, 56
clinical correlates, 56
clinical evaluation, 56
differential diagnosis, 56
EEG pattern, 57
etiology, 56
prognosis, 56
treatment, 56

Periodic discharges (PDs), 39

Permanent VS, 77, 85

Persistent vegetative state (PVS), 26, 73, 77, 85, 97

Phenytoin, 61

PLEDs. See Pseudoperiodic lateralized epileptiform discharges (PLEDs)

Positron emission tomography (PET), 34, 54, 56, 66, 83

LV and, 78

Posterior reversible encephalopathy syndrome (PRES), 150

Potassium channel antibody-associated encephalopathy (VGKC), case study on, 160–61

Prolonged unresponsiveness, states of, 73, 76–7
behavioral characteristics in, 77
electrophysiological findings, 77–8
functional imaging, role of, 78–9
prognosis using electrophysiology, 79

Pseudoperiodic lateralized epileptiform discharges (PLEDs)
ancillary testing, 40
clinical correlates, 40
clinical evaluation, 40
definition, 40
differential diagnosis, 40
EEG recording, 41
etiology, 40
frequency of discharges, 40
prognosis, 40
treatment, 40–41

Riluzole, 123

Secondary generalization, 68

Segmental peripheral neurological disorders, evaluation of, 120

Seizures, 49
complex partial, 52, 54, 56
and EEG, 49–50
frontal lobe seizures, 52–3
in occipital lobes, 58–9
parietal lobe seizures, 56–7
partial seizures, 49
and PLEDs, 39. See also Pseudoperiodic lateralized epileptiform discharges (PLEDs)
simple partial seizure, 54, 56
temporal lobe seizures, 54–5

Sensory neuropathy/ganglionopathy
ancillary testing, 132
clinical correlates, 132
clinical evaluation, 132
differential diagnosis, 132
needle EMG examination, 133
nerve conduction studies, 132
prognosis, 132

Short-latency auditory evoked potentials, 77

Simple partial status epilepticus, occipital
ancillary testing, 68
clinical correlates, 68
clinical evaluation, 68
differential diagnosis, 68
EEG recording, 69
etiology, 68
prognosis, 68
treatment, 68

Simple partial status epilepticus, parietal
ancillary testing, 66
clinical correlates, 66
clinical evaluation, 66
differential diagnosis, 66
EEG recording, 67
etiology, 66
prognosis, 66
treatment, 66

Somatosensory evoked potentials (SSEPs), 2, 8, 20, 22, 26, 46, 78–9, 92, 97
after prolonged cardiac arrest
clinical case study, 104
responses above brachial plexus, absence of, 104–5
in asystolic cardiac arrest
clinical case study, 102
SSEP cortical responses, absence of, 102–3
in diffuse cortical anoxic injury
clinical case study, 100
cortical and subcortical responses, absence of, 100–101
median and tibial nerve SSEP, after traumatic spinal cord injury, 106–7
in midbrain lesion
clinical case study, 98
cortical responses, absence of, 98–9

Spindle beta patterns, in children, 4

Spindle coma
ancillary testing, 22
Spindle coma (cont.)
  clinical correlation, 22
  clinical evaluation, 22
  differential diagnosis, 22
  EEG pattern, 23
  etiology, 22
  prognosis, 22
  treatment, 22
SSEPs. See Somatosensory evoked potentials (SSEPs)
Static encephalopathies
  and diffuse slow theta activity, 6–7
Statin-induced myopathy
  ancillary testing, 146
  clinical correlates, 146
  clinical evaluation, 146
  differential diagnosis, 146
  EMG/nerve conduction studies, 147–8
  prognosis, 146
  treatment, 146
Status epilepticus (SE), 49, 61. See also Nonconvulsive status epilepticus (NCSE)
  frontal lobe CPSE, 62–3
  generalized nonconvulsive status epilepticus, 70–72
  occipital lobe simple partial SE, 68–9
  parietal lobe simple partial SE, 66–7
  temporal lobe CPSE, 64–5
Temporal lobe partial seizures
  ancillary testing, 54
  clinical correlates, 54
  clinical evaluation, 54
  differential diagnosis, 54
  EEG pattern, 55
  etiology, 54
  prognosis, 54
  treatment, 54
Theta, diffuse slow activity
  ancillary testing, 6
  clinical correlates, 6
  clinical evaluation, 6
  differential diagnosis, 6
  EEG pattern, 7
  etiology, 6
  prognosis, 6
  Thigh pain and leg weakness. See Diabetic amyotrophy, diagnosis and treatment of
  Tonic-clonic seizure, 14
Toxic encephalopathy. See Baclofen toxicity
Triphasic waves (TWs), 16, 28, 44, 64, 70, 158
  ancillary testing, 16
  baclofen overdose and, 28–9
  clinical correlates, 16
  clinical evaluation, 16
  differential diagnosis, 16
  EEG pattern, 17
  etiology, 16
  lithium toxicity and, 30–31
  prognosis, 16
  treatment, 16
TWs. See Triphasic waves (TWs)
Unresponsiveness, case study on states of, 152–3. See also Locked-in syndrome (LIS)
Valproate-induced hyperammonemia, case study on, 158–9
Vegetative state (VS), 73, 75, 77, 82, 90, 152, 154
  ancillary testing, 84
  clinical correlates, 84
  clinical evaluation, 84
  differential diagnosis, 84–5
  EEG of, 78
  EEG recording, 85
  etiology, 84
  prognosis, 85
  treatment, 85
Visual evoked potentials (VEPs), 97
  in worsening vision, 108–9
VS. See Vegetative state (VS)